Commencement of INX-0125 Phase 1 Clinical Trial Triggers US$1.0 Million Milestone Payment to INEX
01-Sep-2006
After INEX pays third-party obligations of approximately US$200,000, the Company will forward the remainder of the Hana milestone payment to former INEX noteholders as provided in an agreement with noteholders. This payment will reduce INEX's future contingent payments to the noteholders from US$24.4 million to US$23.6 million.
Organizations
INEX Pharmaceuticals
Hana Biosciences
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.